FDAnews
www.fdanews.com/articles/97098-app-receives-expedited-approval-for-the-first-and-only-generic-cefotetan-disodium-for-injection

APP Receives Expedited Approval for the First and Only Generic Cefotetan Disodium for Injection

August 13, 2007

Abraxis Pharmaceutical Products (APP), the hospital-based business of Abraxis BioScience, Inc. announced the approval from the U.S. Food and Drug Administration (FDA) to market Cefotetan Disodium for Injection, the generic equivalent of AstraZeneca’s Cefotan.
Abraxis